2006
DOI: 10.1016/j.ijid.2005.01.003
|View full text |Cite
|
Sign up to set email alerts
|

Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review

Abstract: As S. pneumoniae is the leading bacterial cause of community-acquired RTIs, and antibacterial resistance is increasing among this species, these findings support the use of telithromycin as first-line therapy in this setting.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2007
2007
2021
2021

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(1 citation statement)
references
References 52 publications
0
1
0
Order By: Relevance
“…These compounds possess a 3-keto group and a proper side chain which can interact with nucleotide A752 in domain II of the 23S rRNA, and showed strong activity against major macrolide-resistant strains [7]. It is known that the ketolide series is not the only class of new macrolides for the effective management of respiratory tract infections.…”
Section: Introductionmentioning
confidence: 99%
“…These compounds possess a 3-keto group and a proper side chain which can interact with nucleotide A752 in domain II of the 23S rRNA, and showed strong activity against major macrolide-resistant strains [7]. It is known that the ketolide series is not the only class of new macrolides for the effective management of respiratory tract infections.…”
Section: Introductionmentioning
confidence: 99%